Effect of Canned Beans of Multiple Varieties in Daily Amounts of 1 Cup and 1/2 Cup on Serum LDL Cholesterol and Other Cardiovascular Disease Risk Biomarkers in Adults With Elevated LDL Cholesterol
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Guelph, Ontario, Canada, N1G 2W1
- Human Nutraceutical Research Unit
-
Toronto, Ontario, Canada, M5C2N8
- Glycemic Index Laboratories, Inc
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female adults (≥18 years)
- BMI 18.5-35 kg/m2
- LDL cholesterol 3.0-5.0 mmol/L
Exclusion Criteria:
- Triglycerides ≥3.0 mmol/L
- Diabetes (fasting blood glucose ≥7.0 mmol/L)
- Blood pressure >140/90 mmHg
- Major medical conditions
- Medical or surgical events requiring hospitalization within the last 3 months
- Medication use that would interfere with the study outcomes (e.g. cholesterol-lowering medications, diabetes-related medications, steroids). All other medications are okay if at a stable (3-month) dose
- Antibiotic use within the last 3 months
- Tobacco product use (>5 times per week)
- Cannabis use during the study
- Probiotic supplement use (could do a 1-month washout before study)
- Dietary fibre supplement use (could do a 1-month washout before study)
- NHPs used for cholesterol lowering or glycemic control. All other NHPs are okay if at a stable (3-month) dose.
- Pulse consumption >4 servings per week
- Food allergy or non-food life-threatening allergy
- Pregnant or breastfeeding
- Alcohol consumption (>14 drinks/week or >4 drinks/sitting)
- Recent or intended significant weight loss or gain (>4 kg in previous 3 months)
- National-level or professional athlete
- Overnight shift worker
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1 cup of canned beans of multiple varieties
Consumption of 1 cup of canned beans of multiple varieties each day for 4 weeks
|
Daily rotation of different varieties of canned beans including black, navy, pinto, red kidney and white kidney
|
|
Experimental: 1/2 cup of canned beans of multiple varieties
Consumption of 1/2 cup of canned beans of multiple varieties each day for 4 weeks
|
Daily rotation of different varieties of canned beans including black, navy, pinto, red kidney and white kidney
|
|
Other: 1 cup of White rice
Consumption of 1 cup of white rice each day for 4 weeks
|
Minute Rice Long Grain White Rice
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fasting serum LDL cholesterol
Time Frame: 4 weeks (28 days)
|
Fasting serum LDL cholesterol will be compared among treatments at study day 29 using ANCOVA and including study day 1 as a covariate
|
4 weeks (28 days)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fasting serum total cholesterol, HDL cholesterol and triglycerides
Time Frame: 4 weeks (28 days)
|
4 weeks (28 days)
|
|
|
Fasting serum glucose and insulin and HOMA-IR
Time Frame: 4 weeks (28 days)
|
Fasting glucose and insulin
|
4 weeks (28 days)
|
|
Fasting serum and fecal short chain fatty acids
Time Frame: 4 weeks (28 days)
|
4 weeks (28 days)
|
|
|
Fecal bile acids
Time Frame: 4 weeks (28 days)
|
4 weeks (28 days)
|
|
|
Gut Microbiota
Time Frame: 4 weeks (28 days)
|
4 weeks (28 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- REB-18-10-045
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.